KR20210057127A - 카베올린-1 펩티드의 건조 분말 제형 및 이의 사용 방법 - Google Patents

카베올린-1 펩티드의 건조 분말 제형 및 이의 사용 방법 Download PDF

Info

Publication number
KR20210057127A
KR20210057127A KR1020217010694A KR20217010694A KR20210057127A KR 20210057127 A KR20210057127 A KR 20210057127A KR 1020217010694 A KR1020217010694 A KR 1020217010694A KR 20217010694 A KR20217010694 A KR 20217010694A KR 20210057127 A KR20210057127 A KR 20210057127A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
amino acid
seq
peptide
peptide comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217010694A
Other languages
English (en)
Korean (ko)
Inventor
로버트 오우. 3세 윌리엄스
앨런 비. 와츠
야지에 장
소윗트리 사하키즈피자른
데일 크리스텐슨
존 제이. 콜렝
Original Assignee
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
렁 쎄라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템, 렁 쎄라퓨틱스 인코포레이티드 filed Critical 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Publication of KR20210057127A publication Critical patent/KR20210057127A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020217010694A 2018-09-10 2019-09-10 카베올린-1 펩티드의 건조 분말 제형 및 이의 사용 방법 Ceased KR20210057127A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729010P 2018-09-10 2018-09-10
US62/729,010 2018-09-10
PCT/US2019/050349 WO2020055824A1 (en) 2018-09-10 2019-09-10 Dry powder formulation of caveolin-1 peptides and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20210057127A true KR20210057127A (ko) 2021-05-20

Family

ID=69778150

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010694A Ceased KR20210057127A (ko) 2018-09-10 2019-09-10 카베올린-1 펩티드의 건조 분말 제형 및 이의 사용 방법

Country Status (9)

Country Link
US (3) US12280088B2 (https=)
EP (1) EP3849581A4 (https=)
JP (2) JP7514840B2 (https=)
KR (1) KR20210057127A (https=)
CN (2) CN112996530B (https=)
AU (1) AU2019339264B2 (https=)
BR (1) BR112021004420A2 (https=)
CA (1) CA3109982A1 (https=)
WO (1) WO2020055824A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110201144B (zh) 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
WO2016138413A1 (en) * 2015-02-27 2016-09-01 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
US20240082342A1 (en) * 2018-11-21 2024-03-14 Board Of Regents, The University Of Texas System Peptide therapeutics for increasing lung cell viability
US20220370544A1 (en) * 2018-11-21 2022-11-24 Board Of Regents, The University Of Texas System Peptide therapeutics for acute and chronic airway and alveolar diseases
WO2020185826A1 (en) * 2019-03-11 2020-09-17 Lung Therapeutics, Inc. Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
EP4138791A1 (en) * 2020-04-20 2023-03-01 Board of Regents, The University of Texas System Biologically active dry powder compositions and method of their manufacture and use
US20230159608A1 (en) * 2020-04-21 2023-05-25 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and uses thereof
US20230226149A1 (en) * 2020-06-19 2023-07-20 Lung Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury
US20250041383A1 (en) * 2021-06-17 2025-02-06 Lung Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of post-acute covid-19
US20250262273A1 (en) * 2021-10-22 2025-08-21 Rein Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of chronic kidney disease
EP4719450A2 (en) * 2023-05-30 2026-04-08 Rein Therapeutics, Inc. Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof
CN121695995A (zh) * 2024-09-18 2026-03-20 深圳翰宇药业股份有限公司 一种多肽药物的粉碎方法
CN119661656A (zh) * 2024-11-20 2025-03-21 华中科技大学同济医学院附属梨园医院 一种靶向拮抗pCAV1的多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
CN1091138A (zh) 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
US20020077283A1 (en) * 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
EP1501479A1 (en) 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
EP2074142A4 (en) * 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
EP2635686B1 (en) 2010-11-05 2018-03-28 The Regents of The University of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
BR112015022831A2 (pt) 2013-03-13 2017-08-22 Forest Laboratories Holdings Ltd Composições farmacêuticas micronizadas
CN110201144B (zh) * 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
WO2015080980A2 (en) 2013-11-26 2015-06-04 E&B Technologies Llc Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
EP3262856B1 (en) * 2015-02-27 2020-02-19 PCMS Holdings, Inc. Systems and methods for secure roll-over of device ownership
WO2016138413A1 (en) * 2015-02-27 2016-09-01 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof

Also Published As

Publication number Publication date
AU2019339264B2 (en) 2025-05-29
CN112996530B (zh) 2025-06-03
US20210260150A1 (en) 2021-08-26
JP2024114982A (ja) 2024-08-23
JP7514840B2 (ja) 2024-07-11
WO2020055824A1 (en) 2020-03-19
CA3109982A1 (en) 2020-03-19
US20240269225A1 (en) 2024-08-15
CN120459067A (zh) 2025-08-12
AU2019339264A1 (en) 2021-03-11
BR112021004420A2 (pt) 2021-06-01
CN112996530A (zh) 2021-06-18
US20250302910A1 (en) 2025-10-02
US12280088B2 (en) 2025-04-22
EP3849581A1 (en) 2021-07-21
WO2020055824A8 (en) 2020-05-14
EP3849581A4 (en) 2022-07-06
JP2022500500A (ja) 2022-01-04
US12280089B2 (en) 2025-04-22

Similar Documents

Publication Publication Date Title
US12280089B2 (en) Dry powder formulation of caveolin-1 peptides and methods of use thereof
JP7737492B2 (ja) Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用
EP4168031A2 (en) Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury
US20250041383A1 (en) Modified caveolin-1 peptides for the treatment of post-acute covid-19
US20250262273A1 (en) Modified caveolin-1 peptides for the treatment of chronic kidney disease
EP3937966A1 (en) Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
KR102958241B1 (ko) Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000